Plain-English translation of NCT06588699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests whether , a medication traditionally used for heart conditions, might help treat a serious liver disease called NASH (nonalcoholic steatohepatitis). In this study, some participants will take the medication once daily, while others will take a placebo (fake pill), to see if the treatment can help the liver heal. Researchers will compare liver health improvements across all groups.
NASH is a condition where fat builds up in the liver and causes inflammation and scarring, but current treatment options are limited. This trial explores whether this medication might reduce liver inflammation and help prevent further liver damage.
You likely qualify if…
You likely don't qualify if…
You will visit the study site multiple times over 24 weeks. At the beginning, you'll have a liver biopsy to confirm your diagnosis and establish a baseline. You'll then be randomly assigned to take either the medication or a placebo pill once daily. Throughout the study, you'll have blood tests and imaging scans to monitor your liver health. At week 24, you'll have a second liver biopsy to see if the treatment helped. The study team will monitor you closely for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States